Article Text

Download PDFPDF
Review of the new APLS guideline (2022): Management of the convulsing child

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors The authors had multiple virtual meetings to create consensus for guideline. MB drafted the algorithm and article, other authors reviewed and edited. RA provided an independent critical appraisal of the guideline.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests AM: GW Pharma - Personal payment, Honorarium; UCB - Honorarium; LivaNova - support to attend meeting; BPNA - Trustee and Professional Support Officer; Epilepsy Scotland - Co-opted Board Member; Ring 20 - Medical Advisory Board Member. NM: Veriton Supply training materials to NM's organisation including demonstration kits of midazolam oromucosal solution for use in training simulations. RFMC: GW Pharma – personal payment, Honorarium, support to attend meeting, local principal investigator in clinical trials; UCB- Honorarium; Eisai – Honorarium, personal payment, support to attend meetings; Zogenix - Honorarium, personal payment, support to attend meetings; Shares in Rize Medical Cannabis & Life Sciences. RA: Chairman of the Independent Data Safety Monitoring Committee for an NIHR HTA-funded study on mental health in children with epilepsy (the ‘MICE’ Study). 2019 – ongoing. Voluntary role.

  • Provenance and peer review Not commissioned; externally peer reviewed.